Table II.
Expression of GLUT-3 and its relationship with clinicopathological characteristics of the validation cohort.
| GLUT-3 expression (n=140) | |||
|---|---|---|---|
| Characteristic | No and low (n=99) | High (n=41) | P-value |
| Age (≥55/<55 years) | 31/68 | 17/24 | 0.250 |
| Sex (F/M) | 9/90 | 6/35 | 0.335 |
| Etiology | 0.473 | ||
| Hepatitis B virus | 93 | 37 | |
| Hepatitis C virus | 1 | 1 | |
| Others | 5 | 3 | |
| Cirrhosis | 0.087 | ||
| Yes | 74 | 36 | |
| No | 25 | 5 | |
| Child-Pugh classification | 0.580 | ||
| A | 92 | 38 | |
| B | 7 | 3 | |
| AFP level, | 0.001 | ||
| ≤400 ng/ml | 63 | 14 | |
| >400 ng/ml | 36 | 27 | |
| Tumor size | 0.031 | ||
| ≤5 cm | 56 | 15 | |
| >5 cm | 43 | 26 | |
| Tumor number | 0.660 | ||
| Single | 80 | 31 | |
| Multiple | 19 | 10 | |
| Vascular invasion | 0.022 | ||
| Yes | 8 | 9 | |
| No | 91 | 32 | |
| Histological differentiation | 0.004 | ||
| Well | 21 | 0 | |
| Moderate | 60 | 26 | |
| Poor | 18 | 15 | |
| TNM stage | 0.144 | ||
| I and II | 79 | 28 | |
| III and IV | 20 | 13 | |
| BCLC stage | 0.403 | ||
| 0 and A | 81 | 31 | |
| B and C | 18 | 10 | |
AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; F, female; GLUT-3, glucose transporter 3; M, male.